Katodritou E - Search Results

1

A rare case of multiple myeloma initially presenting with pseudoachalasia.

Lazaraki G, Nakos A, Katodritou E, Pilpilidis I, Tarpagos A, Katsos I. Lazaraki G, et al. Among authors: katodritou e. Dis Esophagus. 2009;22(6):E21-4. doi: 10.1111/j.1442-2050.2008.00903.x. Epub 2008 Dec 22. Dis Esophagus. 2009. PMID: 19207546

2

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: katodritou e. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.

3

Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report.

Tzilves D, Gatopoulou A, Zervas K, Katodritou E, Patakiouta F, Tarpagos A, Katsos I. Tzilves D, et al. Among authors: katodritou e. World J Gastroenterol. 2007 Apr 7;13(13):2011-3. doi: 10.3748/wjg.v13.i13.2011. World J Gastroenterol. 2007. PMID: 17461509 Free PMC article.

4

Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.

Katodritou E, Kartsios C, Gastari V, Verrou E, Mihou D, Banti A, Lazaraki G, Lazaridou A, Kaloutsi V, Zervas K. Katodritou E, et al. Leuk Res. 2008 Feb;32(2):339-41. doi: 10.1016/j.leukres.2007.04.016. Epub 2007 Jun 8. Leuk Res. 2008. PMID: 17560647

5

Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma.

Katodritou E, Speletas M, Zervas K, Kapetanos D, Georgiou E, Christoforidou A, Pavlitou A, Sion M, Christakis J. Katodritou E, et al. Lab Hematol. 2006;12(1):47-54. doi: 10.1532/LH96.05030. Lab Hematol. 2006. PMID: 16513546

6

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.

Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsonis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos MA; Greek Myeloma Study Group. Zervas K, et al. Among authors: katodritou e. Ann Oncol. 2007 Aug;18(8):1369-75. doi: 10.1093/annonc/mdm178. Ann Oncol. 2007. PMID: 17693650 Free article. Clinical Trial.

7

Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.

Mihou D, Katodritou E, Zervas K. Mihou D, et al. Among authors: katodritou e. Hematology. 2007 Dec;12(6):527-31. doi: 10.1080/10245330701384161. Hematology. 2007. PMID: 17852450

8

Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.

Katodritou E, Verrou E, Hadjiaggelidou C, Gastari V, Laschos K, Kontovinis L, Kapetanos D, Constantinou N, Terpos E, Zervas K. Katodritou E, et al. Am J Hematol. 2008 Sep;83(9):697-701. doi: 10.1002/ajh.21239. Am J Hematol. 2008. PMID: 18626886 Free article.

9

Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

Katodritou E, Gastari V, Verrou E, Hadjiaggelidou C, Varthaliti M, Georgiadou S, Laschos K, Xirou P, Yiannaki E, Constantinou N, Markala D, Zervas K. Katodritou E, et al. Leuk Res. 2009 Aug;33(8):1137-40. doi: 10.1016/j.leukres.2009.01.036. Epub 2009 Feb 27. Leuk Res. 2009. PMID: 19250676

10

Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.

Katodritou E, Dimopoulos MA, Zervas K, Terpos E. Katodritou E, et al. Cancer Treat Rev. 2009 Dec;35(8):738-43. doi: 10.1016/j.ctrv.2009.08.002. Epub 2009 Sep 3. Cancer Treat Rev. 2009. PMID: 19733008 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page